Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARP14_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARP14_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARP14_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARP14_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARP14_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PARP14_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARP14_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARP14_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARP14_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARP14_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182123 | Oral cavity | OSCC | peptidyl-tyrosine modification | 180/7305 | 378/18723 | 3.63e-04 | 2.22e-03 | 180 |
GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
GO:0050730 | Oral cavity | OSCC | regulation of peptidyl-tyrosine phosphorylation | 129/7305 | 264/18723 | 6.70e-04 | 3.75e-03 | 129 |
GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
GO:00458244 | Oral cavity | OSCC | negative regulation of innate immune response | 41/7305 | 71/18723 | 1.05e-03 | 5.40e-03 | 41 |
GO:00507774 | Oral cavity | OSCC | negative regulation of immune response | 97/7305 | 194/18723 | 1.16e-03 | 5.91e-03 | 97 |
GO:0050732 | Oral cavity | OSCC | negative regulation of peptidyl-tyrosine phosphorylation | 35/7305 | 59/18723 | 1.24e-03 | 6.23e-03 | 35 |
GO:00603335 | Oral cavity | OSCC | interferon-gamma-mediated signaling pathway | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:00713535 | Oral cavity | OSCC | cellular response to interleukin-4 | 21/7305 | 33/18723 | 3.63e-03 | 1.51e-02 | 21 |
GO:00706705 | Oral cavity | OSCC | response to interleukin-4 | 21/7305 | 36/18723 | 1.46e-02 | 4.76e-02 | 21 |
GO:0010563110 | Oral cavity | LP | negative regulation of phosphorus metabolic process | 153/4623 | 442/18723 | 1.47e-06 | 3.53e-05 | 153 |
GO:0045936110 | Oral cavity | LP | negative regulation of phosphate metabolic process | 152/4623 | 441/18723 | 2.10e-06 | 4.77e-05 | 152 |
GO:0042326110 | Oral cavity | LP | negative regulation of phosphorylation | 131/4623 | 385/18723 | 2.10e-05 | 3.46e-04 | 131 |
GO:003434114 | Oral cavity | LP | response to interferon-gamma | 57/4623 | 141/18723 | 2.63e-05 | 4.21e-04 | 57 |
GO:000283211 | Oral cavity | LP | negative regulation of response to biotic stimulus | 46/4623 | 108/18723 | 3.31e-05 | 5.02e-04 | 46 |
GO:0001933110 | Oral cavity | LP | negative regulation of protein phosphorylation | 117/4623 | 342/18723 | 4.34e-05 | 6.22e-04 | 117 |
GO:007134612 | Oral cavity | LP | cellular response to interferon-gamma | 48/4623 | 118/18723 | 9.16e-05 | 1.15e-03 | 48 |
GO:000195911 | Oral cavity | LP | regulation of cytokine-mediated signaling pathway | 58/4623 | 150/18723 | 1.00e-04 | 1.24e-03 | 58 |
GO:004508811 | Oral cavity | LP | regulation of innate immune response | 78/4623 | 218/18723 | 1.57e-04 | 1.78e-03 | 78 |
GO:006075911 | Oral cavity | LP | regulation of response to cytokine stimulus | 61/4623 | 162/18723 | 1.61e-04 | 1.81e-03 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP14 | SNV | Missense_Mutation | | c.2578C>G | p.Leu860Val | p.L860V | Q460N5 | protein_coding | tolerated(0.53) | benign(0.047) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
PARP14 | SNV | Missense_Mutation | novel | c.2665N>A | p.Glu889Lys | p.E889K | Q460N5 | protein_coding | tolerated(0.14) | benign(0.037) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP14 | SNV | Missense_Mutation | | c.2473N>A | p.Glu825Lys | p.E825K | Q460N5 | protein_coding | deleterious(0.02) | possibly_damaging(0.749) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP14 | SNV | Missense_Mutation | | c.4653N>T | p.Met1551Ile | p.M1551I | Q460N5 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP14 | SNV | Missense_Mutation | | c.142N>T | p.Pro48Ser | p.P48S | Q460N5 | protein_coding | tolerated(0.07) | possibly_damaging(0.609) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PARP14 | SNV | Missense_Mutation | novel | c.5212N>A | p.Val1738Met | p.V1738M | Q460N5 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARP14 | SNV | Missense_Mutation | novel | c.2375G>C | p.Cys792Ser | p.C792S | Q460N5 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PARP14 | SNV | Missense_Mutation | | c.763N>C | p.Gly255Arg | p.G255R | Q460N5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PARP14 | SNV | Missense_Mutation | | c.4396G>C | p.Asp1466His | p.D1466H | Q460N5 | protein_coding | tolerated(0.13) | benign(0.048) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PARP14 | SNV | Missense_Mutation | | c.3835N>G | p.Gln1279Glu | p.Q1279E | Q460N5 | protein_coding | tolerated(1) | benign(0.372) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |